REFERENCES
- Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, et al.: Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 31, 1105–1113, 2011.
- Singh BN, Fu J, Srivastava RK, and Shankar S: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 6, e27306, 2011.
- Chen JK, Taipale J, Cooper MK, and Beachy PA: Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16, 2743–2748, 2002.
- Yao J, An Y, Wie JS, Ji ZL, Lu ZP, et al.: Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Med Wkly 141, w13208, 2011.
- Kumar SK, Roy I, Anchoori RK, Fazli S, Maitra A, et al.: Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem 16, 2764–2768, 2008.
- Singh BN, Shankar S, and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82, 1807–1821, 2011.
- Hsu YC, and Liou YM: The anti-cancer effects of (-)-epigalocathine-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. J Cell Physiol 226, 2721–2730, 2011.
- Yang CS, Wang X, Lu G, and Picinich SC: Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9, 429–439, 2009.
- Hou Z, Sang S, You H, Lee MJ, Hong J, et al.: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 65, 8049–8056, 2005.
- Hong J, Lu H, Meng X, Ryu JH, Hara Y, et al.: Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 62, 7241–7246, 2002.
- Yasugi K, Nagasaki Y, Kato M, Kataoka K: Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. J Control Release 62, 89–100, 1999.
- Ghosh SK, Khatua PK, and Bhattacharya SC: Physicochemical characteristics of reverse micelles of polyoxyethylene nonyl phenol in different organic solvents. J Colloid Interface Sci 279, 523–532, 2004.
- Sun LM, Zhang CL, Li P: Characterization, antimicrobial activity, and mechanism of a high-performance (-)-epigallocatechin-3-gallate (EGCG)-CuII/polyvinyl alcohol (PVA) nanofibrous membrane. J Agric Food Chem 59, 5087–5092, 2011.
- Kim JY, Kim S, Pinal R, Park K: Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. J Control Release 152, 13–20, 2011.
- Min KH, Park K, Kim YS, Bae SM, Lee S, et al.: Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 127, 208–218, 2008.
- Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, et al.: Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67, 2187–2196, 2007.
- Wheeler DL, Dunn EF, and Harari PM: Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7, 493–507, 2010.
- Cano CE, Motoo Y, and Iovanna JL: Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Scientific World Journal 10, 1947–1957, 2010.